Similar proportions of older women with node-negative and node-positive breast cancer had Oncotype Dx breast recurrence scores that would qualify them for adjuvant chemotherapy, according to study results.
The findings, presented during an American Society of Breast Surgeons Annual Meeting press briefing, indicate sentinel lymph node biopsy may not be useful in making adjuvant chemotherapy decisions for patients aged 70 years or older with hormone receptor-positive, HER2-negative, American Joint Committee on Cancer (AJCC) clinical stage I breast cancer.
“However, certain tumor factors may